This Once-Dominant Healthcare Stock Down 50% Is Finally Ready for a Comeback

A few years ago, Pfizer (PFE -2.86%) was on top of the world when it came to earnings and stock price performance. The pharma giant recorded a record of $100 billion in sales back in 2022, and saw its shares rise 60% over nearly two years through a peak in late 2021. This was in early pandemic times, as the company's coronavirus treatment and vaccine generated enormous levels of revenue. But as demand for those products waned in the later stages of the health crisis, Pfizer saw revenue drop significantly. T ...